Skip to main content
Erschienen in: European Radiology 5/2019

14.12.2018 | Hepatobiliary-Pancreas

How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?

verfasst von: Hong Seon Lee, Myeong-Jin Kim, Chansik An

Erschienen in: European Radiology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To investigate the diagnostic accuracy of each LR-M feature defined in version 2017 of the Liver Imaging Reporting and Data System (LI-RADS) and determine the optimal LR-M feature for differentiating combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and hepatocellular carcinoma (HCC) on gadoxetate-enhanced magnetic resonance imaging (MRI).

Methods

Ninety-nine patients with pathologically proven cHCC-CCA (n = 33) or HCC (n = 66) after surgery were identified. Two radiologists retrospectively assessed preoperative gadoxetate-enhanced MRI for features favoring non-HCC malignancies (LR-M features) according to LI-RADS version 2017. Multivariate logistic regression analysis was performed to determine the independent differential features. The sensitivity and specificity for diagnosing cHCC-CCA were calculated for each LR-M feature.

Results

Targetoid appearance showed the highest sensitivity (75.8%, 95% confidence interval [CI] 60.6%, 87.3%) to correctly identify cHCC-CCA as LR-M. At least one LR-M feature was observed in 31 (93.9%) patients with cHCC-CCA and 34 (51.5%) patients with HCC. The sensitivity and specificity for diagnosing cHCC-CCA using the presence of any one of the LR-M features were 93.9% (95% CI 80.7, 98.9) and 48.5% (95% CI 41.9, 51.0), respectively. The presence of three LR-M features yielded the highest diagnostic accuracy of 80.8% (95% CI 72.1, 86.1) with a reduced sensitivity of 54.5% (95% CI 41.4, 62.5).

Conclusion

The majority of cHCC-CCA cases can be properly categorized as LR-M when any one of the LR-M features defined in the LI-RADS version 2017 is used as a determiner. However, approximately half of HCC cases also show at least one LR-M feature.

Key Points

• Targetoid appearance, including rim APHE, peripheral “washout” appearance, and delayed central enhancement, was the LR-M feature that identified cHCC-CCA as a non-HCC malignancy with the highest sensitivity.
• Most cHCC-CCA cases can be properly categorized as LR-M when the presence of any one of the LR-M features was used as the determiner.
• Approximately half of HCC cases also showed at least one LR-M feature.
Literatur
1.
Zurück zum Zitat Brunt E, Aishima S, Clavien PA et al (2018) cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 68:113–126CrossRefPubMed Brunt E, Aishima S, Clavien PA et al (2018) cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 68:113–126CrossRefPubMed
2.
Zurück zum Zitat Yoon YI, Hwang S, Lee YJ et al (2016) Postresection outcomes of combined hepatocellular carcinoma-cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Gastrointest Surg 20:411–420CrossRefPubMed Yoon YI, Hwang S, Lee YJ et al (2016) Postresection outcomes of combined hepatocellular carcinoma-cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Gastrointest Surg 20:411–420CrossRefPubMed
3.
Zurück zum Zitat Yin X, Zhang BH, Qiu SJ et al (2012) Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 19:2869–2876CrossRefPubMed Yin X, Zhang BH, Qiu SJ et al (2012) Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 19:2869–2876CrossRefPubMed
4.
Zurück zum Zitat Magistri P, Tarantino G, Serra V, Guidetti C, Ballarin R, Di Benedetto F (2017) Liver transplantation and combined hepatocellular-cholangiocarcinoma: feasibility and outcomes. Dig Liver Dis 49:467–470CrossRefPubMed Magistri P, Tarantino G, Serra V, Guidetti C, Ballarin R, Di Benedetto F (2017) Liver transplantation and combined hepatocellular-cholangiocarcinoma: feasibility and outcomes. Dig Liver Dis 49:467–470CrossRefPubMed
5.
Zurück zum Zitat Vilchez V, Shah MB, Daily MF et al (2016) Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB (Oxford) 18:29–34CrossRef Vilchez V, Shah MB, Daily MF et al (2016) Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB (Oxford) 18:29–34CrossRef
6.
Zurück zum Zitat European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236 European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
7.
Zurück zum Zitat Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380CrossRefPubMed Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380CrossRefPubMed
8.
Zurück zum Zitat Fowler KJ, Sheybani A, Parker RA 3rd et al (2013) Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 201:332–339CrossRefPubMed Fowler KJ, Sheybani A, Parker RA 3rd et al (2013) Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 201:332–339CrossRefPubMed
9.
Zurück zum Zitat Fraum TJ, Tsai R, Rohe E et al (2018) Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the Liver Imaging Reporting and Data System version 2014. Radiology 286:158–172CrossRefPubMed Fraum TJ, Tsai R, Rohe E et al (2018) Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the Liver Imaging Reporting and Data System version 2014. Radiology 286:158–172CrossRefPubMed
10.
Zurück zum Zitat Mao Y, Xu S, Hu W et al (2017) Imaging features predict prognosis of patients with combined hepatocellular-cholangiocarcinoma. Clin Radiol 72:129–135CrossRefPubMed Mao Y, Xu S, Hu W et al (2017) Imaging features predict prognosis of patients with combined hepatocellular-cholangiocarcinoma. Clin Radiol 72:129–135CrossRefPubMed
11.
Zurück zum Zitat Park SH, Lee SS, Yu E et al (2017) Combined hepatocellular-cholangiocarcinoma: gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging 46:267–280CrossRefPubMed Park SH, Lee SS, Yu E et al (2017) Combined hepatocellular-cholangiocarcinoma: gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging 46:267–280CrossRefPubMed
12.
Zurück zum Zitat Sheng RF, Xie YH, Ji Y et al (2016) MR comparative study of combined hepatocellular-cholangiocarcinoma in normal, fibrotic, and cirrhotic livers. Abdom Radiol (NY) 41:2102–2114CrossRef Sheng RF, Xie YH, Ji Y et al (2016) MR comparative study of combined hepatocellular-cholangiocarcinoma in normal, fibrotic, and cirrhotic livers. Abdom Radiol (NY) 41:2102–2114CrossRef
13.
14.
Zurück zum Zitat Shetty AS, Fowler KJ, Brunt EM, Agarwal S, Narra VR, Menias CO (2014) Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging 39:310–322CrossRefPubMed Shetty AS, Fowler KJ, Brunt EM, Agarwal S, Narra VR, Menias CO (2014) Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging 39:310–322CrossRefPubMed
15.
Zurück zum Zitat de Campos RO, Semelka RC, Azevedo RM et al (2012) Combined hepatocellular carcinoma-cholangiocarcinoma: report of MR appearance in eleven patients. J Magn Reson Imaging 36:1139–1147CrossRefPubMed de Campos RO, Semelka RC, Azevedo RM et al (2012) Combined hepatocellular carcinoma-cholangiocarcinoma: report of MR appearance in eleven patients. J Magn Reson Imaging 36:1139–1147CrossRefPubMed
16.
Zurück zum Zitat Hwang J, Kim YK, Park MJ et al (2012) Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging 36:881–889CrossRefPubMed Hwang J, Kim YK, Park MJ et al (2012) Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging 36:881–889CrossRefPubMed
17.
Zurück zum Zitat Elsayes KM, Hooker JC, Agrons MM et al (2017) 2017 version of LI-RADS for CT and MR imaging: an update. Radiographics 37:1994–2017CrossRefPubMed Elsayes KM, Hooker JC, Agrons MM et al (2017) 2017 version of LI-RADS for CT and MR imaging: an update. Radiographics 37:1994–2017CrossRefPubMed
18.
Zurück zum Zitat Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR (2018) LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 43:149–157CrossRef Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR (2018) LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 43:149–157CrossRef
19.
Zurück zum Zitat Potretzke TA, Tan BR, Doyle MB, Brunt EM, Heiken JP, Fowler KJ (2016) Imaging features of biphenotypic primary liver carcinoma (hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS analysis of CT and MRI features in 61 cases. AJR Am J Roentgenol 207:25–31CrossRefPubMed Potretzke TA, Tan BR, Doyle MB, Brunt EM, Heiken JP, Fowler KJ (2016) Imaging features of biphenotypic primary liver carcinoma (hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS analysis of CT and MRI features in 61 cases. AJR Am J Roentgenol 207:25–31CrossRefPubMed
21.
Zurück zum Zitat Kim YY, An C, Kim S, Kim MJ (2018) Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI. Eur Radiol 28:2038–2046CrossRefPubMed Kim YY, An C, Kim S, Kim MJ (2018) Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI. Eur Radiol 28:2038–2046CrossRefPubMed
23.
Zurück zum Zitat An C, Park S, Chung YE et al (2017) Curative resection of single primary hepatic malignancy: liver imaging reporting and data system category LR-M portends a worse prognosis. AJR Am J Roentgenol 209:576–583CrossRefPubMed An C, Park S, Chung YE et al (2017) Curative resection of single primary hepatic malignancy: liver imaging reporting and data system category LR-M portends a worse prognosis. AJR Am J Roentgenol 209:576–583CrossRefPubMed
24.
Zurück zum Zitat Tang A, Bashir MR, Corwin MT et al (2018) Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 286:29–48CrossRefPubMed Tang A, Bashir MR, Corwin MT et al (2018) Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 286:29–48CrossRefPubMed
25.
Zurück zum Zitat Park HJ, Jang KM, Kang TW et al (2016) Identification of imaging predictors discriminating different primary liver tumours in patients with chronic liver disease on gadoxetic acid-enhanced MRI: a classification tree analysis. Eur Radiol 26:3102–3111CrossRefPubMed Park HJ, Jang KM, Kang TW et al (2016) Identification of imaging predictors discriminating different primary liver tumours in patients with chronic liver disease on gadoxetic acid-enhanced MRI: a classification tree analysis. Eur Radiol 26:3102–3111CrossRefPubMed
26.
Zurück zum Zitat Park MJ, Kim YK, Park HJ, Hwang J, Lee WJ (2013) Scirrhous hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: emphasis on the differentiation of intrahepatic cholangiocarcinoma. J Comput Assist Tomogr 37:872–881CrossRefPubMed Park MJ, Kim YK, Park HJ, Hwang J, Lee WJ (2013) Scirrhous hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: emphasis on the differentiation of intrahepatic cholangiocarcinoma. J Comput Assist Tomogr 37:872–881CrossRefPubMed
27.
Zurück zum Zitat Park HJ, Kim YK, Park MJ, Lee WJ (2013) Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 38:793–801CrossRefPubMed Park HJ, Kim YK, Park MJ, Lee WJ (2013) Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 38:793–801CrossRefPubMed
28.
Zurück zum Zitat Kang Y, Lee JM, Kim SH, Han JK, Choi BI (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264:751–760CrossRefPubMed Kang Y, Lee JM, Kim SH, Han JK, Choi BI (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264:751–760CrossRefPubMed
29.
Zurück zum Zitat Li R, Yang D, Tang CL et al (2016) Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC Cancer 16:158CrossRefPubMedPubMedCentral Li R, Yang D, Tang CL et al (2016) Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC Cancer 16:158CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Horvat N, Nikolovski I, Long N et al (2018) Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014. Abdom Radiol (NY) 43:169–178CrossRef Horvat N, Nikolovski I, Long N et al (2018) Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014. Abdom Radiol (NY) 43:169–178CrossRef
Metadaten
Titel
How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
verfasst von
Hong Seon Lee
Myeong-Jin Kim
Chansik An
Publikationsdatum
14.12.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 5/2019
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-018-5893-1

Weitere Artikel der Ausgabe 5/2019

European Radiology 5/2019 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.